ClinicalTrials.gg
RecruitingNCT07362459Updated Jan 23, 2026

A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.

A Phase 3 interventional study of SCTB14 and Pembrolizumab in Non-Small Cell Lung Carcinoma (NSCLC), sponsored by Sinocelltech Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by Sinocelltech Ltd. (part of Sinocelltech Group Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
246
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 1,882 studies in Carcinoma, Non-Small-Cell Lung with a site in China — 762 open to participants now, 987 under way, 202 of them phase 3. Carcinoma, Non-Small-Cell Lung · China.

Planned enrollment
454th of 1,595
246 · median 100
Started
2025
with 207 others
Phase 3
366 of 1,882
103 open now
Primary completion
2027-07
later than 585 of 986 live
Registered
1,694th of 1,882
by date

Among the 1,882 studies in Carcinoma, Non-Small-Cell Lung with a site in China, this one is the 454th largest by planned enrollment of the 1,595 interventional ones that give a count, is one of 208 that started in 2025, is one of 366 in phase 3, reaches primary completion later than 585 of the 986 other live ones, and was the 1,694th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

762 of the 1,882 studies in Carcinoma, Non-Small-Cell Lung with a site in China are open now. Recruiting first, the newest first:

757 more — sign in →

All 762 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,882 studies in Carcinoma, Non-Small-Cell Lung with a site in China, or all of them as a file.
02

Study summary

This Phase III, randomized, double-blind study compares the efficacy and safety of SCTB14 versus pembrolizumab as first-line treatment in patients with driver gene-negative, TPS ≥10% locally advanced or metastatic non-small cell lung cancer (NSCLC). The primary objective is to assess superiority of SCTB14 over pembrolizumab in prolonging progression-free survival. Safety will be closely monitored.

03

Conditions studied

  • Non-Small Cell Lung Carcinoma (NSCLC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign the written form prior to screening.
  2. Age ≥ 18 years, both male and female.
  3. Performance Status score of 0 to 1.
  4. An expected survival of ≥ 3 months.
  5. or cytologically confirmed, unresectable locally advanced (Stage IIIB/IIIC) or (Stage IV) Non-Small Cell Lung Cancer (NSCLC) that is not amenable to curative surgery or radical concurrent/sequential chemoradiotherapy.
  6. For subjects with non-squamous cell carcinoma, as well as non-smoking subjects with squamous cell carcinoma containing mixed adenocarcinoma components, confirmation of the absence of EGFR sensitizing mutations or ALK gene rearrangements from tumor tissue is required prior to enrollment.
  7. Subjects must provide a histology sample suitable for testing, with a Tumor Proportion Score (TPS) ≥ 10%.
  8. No prior systemic anti-tumor therapy for the studied disease.
  9. At least one measurable non-CNS lesion according to v1.1 criteria.
  10. Adequate function of major organs.

Exclusion criteria

Exclusion Criteria:

  1. Known actionable driver gene mutations such as ROS1 fusion, BRAF V600E mutation, NTRK fusion, MET exon 14 skipping mutation, and RET fusion mutation.
  2. Received non-specific immunomodulatory therapy or drugs within 2 weeks before the first dose; received traditional Chinese medicine with antineoplastic indications within 1 week before the first dose.
  3. Prior thoracic radiotherapy; or local anti-tumor therapy within 2 weeks before first dosing.
  4. Prior treatment with antitumor immunotherapy, antiangiogenic therapy, or other small molecule tyrosine kinase inhibitor (TKI)-based antitumor drugs.
  5. subjects with or compression involving the brainstem, meninges, or spinal cord, or those with active or multiple brain metastases.
  6. Imaging demonstrates tumor invasion of major blood vessels, significant necrosis or cavitation within the primary tumor lesions, or the presence of lymphangitic carcinomatosis.
  7. Imaging demonstrates tumor invasion or compression of adjacent vital organs or carries a risk of developing an esophagotracheal fistula or esophagopleural fistula.
  8. History of hypertensive crisis or hypertensive encephalopathy, or the presence of uncontrolled hypertension despite medication, or poorly controlled diabetes despite pharmacotherapy.
  9. A history of arterial thrombosis, deep vein thrombosis, cerebral infarction, , or significant vascular disease within 6 months prior to enrollment.
  10. A history of myocardial infarction, unstable angina, cardiac insufficiency with (NYHA) class ≥ III, or severe arrhythmia uncontrolled by medication within 6 months prior to enrollment.
  11. The presence of any active disease or a history of autoimmune disease with an anticipated recurrence.
  12. A history of esophageal/gastric varices, severe ulcer, abdominal fistula, intra-abdominal abscess, gastrointestinal perforation and/or fistula, acute gastrointestinal bleeding, intestinal obstruction, or extensive intestinal resection within 6 months prior to the first dose.
  13. A history of bleeding tendency, high bleeding risk, or coagulation dysfunction,.
  14. The presence of other malignant tumors.
  15. Toxicities from prior /adjuvant therapy, surgery, radiotherapy, or other previous antitumor treatments have not recovered to Grade 0-1.
  16. Receipt of a live or attenuated vaccine within 4 weeks prior to the first dose, or a plan to receive a live or attenuated vaccine during the study period; however, the use of inactivated vaccines is permitted.
  17. Presence of any of the following infectious conditions: a) severe infection within 4 weeks prior to the first dose; b) active infection within 2 weeks prior to enrollment; c) active tuberculosis; d) positive antibody; e) active or C; f) known active syphilis.
  18. Major surgery planned or anticipated during the study period, or unhealed tissue present before enrollment..
  19. Presence of symptomatic or recurrent pleural effusion, pericardial effusion, or ascites requiring drainage.
  20. A history of non-infectious pneumonia requiring treatment or the presence of interstitial lung disease
  21. A history of allogeneic organ transplantation or hematopoietic stem cell transplantation.
  22. Known to any component of the drug or a documented history of severe hypersensitivity reactions to any other monoclonal antibody.
  23. Current participation in another clinical trial, with the exception of observational (non-interventional) studies or the follow-up phase of an interventional trial.
  24. Pregnancy or lactation in female subjects.
  25. A known history of alcohol or drug addiction, psychiatric disorders, or drug abuse in the subject.
  26. Tumor-induced conditions or symptoms associated with a high medical risk.
  27. Any other condition deemed by the investigator to be inappropriate for enrollment.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
246 participants (estimated)

Study arms

  • Experimental
    SCTB14

    intravenous infusion on Day 1 of each 3-week cycle

    Drug: SCTB14

  • Active comparator
    Pembrolizumab

    200mg, intravenous infusion on Day 1 of each 3-week cycle

    Drug: Pembrolizumab

Interventions

  • DrugSCTB14

    SCTB14 is administered at selected dose by intravenous infusion on Day 1 of each 3-week cycle.

  • Pembrolizumab is administered at a fixed dose of 200 mg by intravenous infusion on Day 1 of each 3-week cycle.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review

    Time from randomization to first documented progression or death (whichever occurs first).

    Time frame: Up to approximately 1.5 years

Secondary outcomes

  1. overall survival

    The time from the date of randomization to the date of death from any cause.

    Time frame: Up to approximately 5 years

  2. Progression-Free Survival (PFS) as Assessed by Investigator

    Time from randomization to first documented progression or death (whichever occurs first).

    Time frame: Up to approximately 1.5 years

  3. Confirmed Objective Response Rate (ORR) Assessed by Blinded Independent Central Review

    The proportion of subjects with a best overall confirmed response of Complete Response (CR) or Partial Response (PR)

    Time frame: Up to approximately 1.5 years

  4. Disease Control Rate (DCR) Assessed by Blinded Independent Central Review

    The proportion of patients with a best overall response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD).

    Time frame: Up to approximately 1.5 years

  5. Duration of Response (DOR)Assessed by Blinded Independent Central Review

    The time from the first documented objective response (Complete Response \[CR\] or Partial Response \[PR\]) to the first documented disease progression or death from any cause, whichever occurs first.

    Time frame: Up to approximately 1.5 years

  6. Time to Response (TTR)

    Time from the date of randomization to the first documented objective response (Complete Response \[CR\] or Partial Response \[PR\]

    Time frame: Up to approximately 1.5 years

  7. Treatment-Emergent Adverse Event(TEAE)

    Any adverse event that occurs or worsens in severity after the initiation of study drug administration

    Time frame: The first dose of study drug until 30 days (±7 days) after the last dose

  8. Serious adverse events (SAEs)

    An adverse medical event occurring after a subject receives the investigational drug that results in any of the following outcomes: death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.

    Time frame: From the first dose of study druguntil 60 days after the last dose.

  9. immune-related adverse events (irAEs)

    All grades of adverse drug reactions (ADRs) that occur after a subject receives the investigational drug and are assessed as having a causal relationship to an immune-mediated mechanism.

    Time frame: From the first dose of study druguntil 60 days after the last dose

  10. PD-L1 expression

    The correlationship between PD-L1 expression and anti-tumor activity.

    Time frame: Up to approximately 1.5 years.

  11. Quality of Life Questionnaire

    Change in Health-Related Quality of Life EORTC QLQ-C30

    Time frame: Up to approximately 1.5 years.

  12. Quality of Life Questionnaire

    Change in Health-Related Quality of Life QLQ-LC13

    Time frame: Up to approximately 1.5 years

  13. Anti-drug antibodies (ADA)

    Number and percentage of subjects with anti-drug antibodies (ADA) to SCTB14

    Time frame: Up to approximately 1.5 years

  14. Pharmacokinetic (PK)

    Serum concentration of SCTB14 at different time points

    Time frame: Up to approximately 1.5 years.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jul 2027, 19 months after the start.

Of 314 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 19 months is below that.

Counting every sponsor, half of 423 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2026
First posted
Jan 23, 2026
StartActual
Dec 30, 2025
Primary completionEst.
Jul 2027
CompletionEst.
Sep 2029
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07362459
Lead sponsor
Sinocelltech Ltd.
Responsible party
Sponsor
First posted
Jan 23, 2026
Start date
Dec 30, 2025
Primary completion
Jul 2027 (estimated)
Completion
Sep 2029 (estimated)
Last update
Jan 23, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion